We first treated glioblastoma cells with cycloheximide to block de novo protein synthesis and then added Trametinib to inhibit the MAPK pathway, which resulted in a dramatic decrease in the half-life of ZNF263 (Fig. 5a). This evidence concerns the gene ZNF263 and glioblastoma.